Related Experiment Video
Updated: May 30, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Evaluating preclinical efficacy
1Department of Pathology, University of Florida, College of Medicine, Gainesville, FL 32610, USA. atkinson@ufl.edu
Science Translational Medicine
|August 19, 2011
Abstract:
Recent disappointing results of clinical trials seeking type 1 diabetes (T1D) reversal suggest the need for a reevaluation of our translational efforts. This Commentary explores the need for standards in evaluating therapeutic efficacy in preclinical models of T1D.
Insights
Clinical trials for type 1 diabetes reversal have yielded disappointing results. This commentary emphasizes the need for standardized methods to evaluate therapeutic efficacy in preclinical type 1 diabetes models.
Area of Science:
- Immunology
- Endocrinology
- Translational Medicine
Background:
- Recent clinical trials aiming for type 1 diabetes (T1D) reversal have shown unsatisfactory outcomes.
- This necessitates a critical review of current translational strategies in T1D research.
Purpose of the Study:
- To highlight the urgent need for standardized criteria in assessing the efficacy of therapeutic interventions for T1D in preclinical settings.
- To advocate for improved evaluation methodologies to enhance the success rate of future T1D treatments.
Main Methods:
- This commentary analyzes the current landscape of T1D preclinical research and clinical trial outcomes.
- It discusses the limitations of existing methods for evaluating therapeutic efficacy.
- It proposes the development and adoption of standardized protocols.
Main Results:
- Current preclinical models and efficacy evaluations may not accurately predict clinical success in T1D reversal.
- A lack of standardized evaluation metrics hinders reliable comparisons across studies.
- Implementing standardized methods is crucial for advancing T1D therapeutic development.
Conclusions:
- The disappointing results in T1D reversal trials underscore the inadequacy of current preclinical evaluation standards.
- Establishing robust, standardized methods for assessing therapeutic efficacy in preclinical T1D models is essential.
- Standardization will improve the translation of promising therapies from bench to bedside for type 1 diabetes.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...